{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T10:01:43Z","timestamp":1777370503279,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T00:00:00Z","timestamp":1609891200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["#14\/06037-6"],"award-info":[{"award-number":["#14\/06037-6"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["#16\/01639-3"],"award-info":[{"award-number":["#16\/01639-3"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["#14\/50947-7"],"award-info":[{"award-number":["#14\/50947-7"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","award":["#13\/08135-2"],"award-info":[{"award-number":["#13\/08135-2"]}],"id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["#460750\/2014-"],"award-info":[{"award-number":["#460750\/2014-"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["#305158\/2013-9"],"award-info":[{"award-number":["#305158\/2013-9"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1007\/s10637-020-01028-8","type":"journal-article","created":{"date-parts":[[2021,1,6]],"date-time":"2021-01-06T01:03:03Z","timestamp":1609894983000},"page":"736-746","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["NT157, an IGF1R-IRS1\/2 inhibitor, exhibits antineoplastic effects in pre-clinical models of chronic myeloid leukemia"],"prefix":"10.1007","volume":"39","author":[{"given":"Renata","family":"Scopim-Ribeiro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00e3o Agostinho","family":"Machado-Neto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher A.","family":"Eide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Luiz","family":"Coelho-Silva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna Alves","family":"Fenerich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaqueline Cristina","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscila Santos","family":"Scheucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha L.","family":"Savage Stevens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula","family":"de Melo Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara T.","family":"Olalla Saad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonardo","family":"de Carvalho Palma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorena Lobo","family":"de Figueiredo-Pontes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda Pinto","family":"Sim\u00f5es","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Magalh\u00e3es","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina E.","family":"Tognon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian J.","family":"Druker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Traina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,6]]},"reference":[{"key":"1028_CR1","doi-asserted-by":"publisher","first-page":"3343","DOI":"10.1182\/blood.V96.10.3343","volume":"96","author":"MW Deininger","year":"2000","unstructured":"Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343\u20133356","journal-title":"Blood"},{"key":"1028_CR2","doi-asserted-by":"publisher","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","volume":"110","author":"T O\u2019Hare","year":"2007","unstructured":"O\u2019Hare T, Eide CA, Deininger MW (2007) Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood 110:2242\u20132249","journal-title":"Blood"},{"key":"1028_CR3","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1038\/leu.2015.168","volume":"29","author":"TP Hughes","year":"2015","unstructured":"Hughes TP, Saglio G, Quintas-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley-Garelik MB, Ukropec J, Hochhaus A (2015) BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia 29:1832\u20131838","journal-title":"Leukemia"},{"key":"1028_CR4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1016\/S0140-6736(13)62120-0","volume":"385","author":"JF Apperley","year":"2015","unstructured":"Apperley JF (2015) Chronic myeloid leukaemia. Lancet 385:1447\u20131459","journal-title":"Lancet"},{"key":"1028_CR5","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1126\/science.8372354","volume":"261","author":"LM Wang","year":"1993","unstructured":"Wang LM, Myers MG Jr, Sun XJ, Aaronson SA, White M, Pierce JH (1993) IRS-1: essential for insulin- and IL-4-stimulated mitogenesis in hematopoietic cells. Science 261:1591\u20131594","journal-title":"Science"},{"key":"1028_CR6","doi-asserted-by":"publisher","first-page":"22171","DOI":"10.1016\/S0021-9258(18)41650-X","volume":"267","author":"F Folli","year":"1992","unstructured":"Folli F, Saad MJ, Backer JM, Kahn CR (1992) Insulin stimulation of phosphatidylinositol 3-kinase activity and association with insulin receptor substrate 1 in liver and muscle of the intact rat. J Biol Chem 267:22171\u201322177","journal-title":"J Biol Chem"},{"key":"1028_CR7","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1126\/science.8316835","volume":"260","author":"EY Skolnik","year":"1993","unstructured":"Skolnik EY, Batzer A, Li N, Lee CH, Lowenstein E, Mohammadi M, Margolis B, Schlessinger J (1993) The function of GRB2 in linking the insulin receptor to Ras signaling pathways. Science 260:1953\u20131955","journal-title":"Science"},{"key":"1028_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0014-5793(02)03845-0","volume":"535","author":"F Traina","year":"2003","unstructured":"Traina F, Carvalheira JB, Saad MJ, Costa FF, Saad ST (2003) BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. FEBS Lett 535:17\u201322","journal-title":"FEBS Lett"},{"key":"1028_CR9","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1016\/j.bbamcr.2011.04.002","volume":"1813","author":"JA Machado-Neto","year":"2011","unstructured":"Machado-Neto JA, Favaro P, Lazarini M, Costa FF, Olalla Saad ST, Traina F (2011) Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt\/mTOR and MAPK pathways in K562 cells. Biochim Biophys Acta 1813:1404\u20131411","journal-title":"Biochim Biophys Acta"},{"key":"1028_CR10","doi-asserted-by":"publisher","first-page":"4383","DOI":"10.1158\/0008-5472.CAN-12-3385","volume":"73","author":"H Reuveni","year":"2013","unstructured":"Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M, Bar-Eli M, Levitzki A (2013) Therapeutic destruction of insulin receptor substrates for cancer treatment. Cancer Res 73:4383\u20134394","journal-title":"Cancer Res"},{"key":"1028_CR11","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1158\/1535-7163.MCT-13-0842","volume":"13","author":"N Ibuki","year":"2014","unstructured":"Ibuki N, Ghaffari M, Reuveni H, Pandey M, Fazli L, Azuma H, Gleave ME, Levitzki A, Cox ME (2014) The tyrphostin NT157 suppresses insulin receptor substrates and augments therapeutic response of prostate cancer. Mol Cancer Ther 13:2827\u20132839","journal-title":"Mol Cancer Ther"},{"key":"1028_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.3389\/fendo.2015.00074","volume":"6","author":"C Garofalo","year":"2015","unstructured":"Garofalo C, Capristo M, Mancarella C, Reunevi H, Picci P, Scotlandi K (2015) Preclinical effectiveness of selective inhibitor of IRS-1\/2 NT157 in osteosarcoma cell lines. Front Endocrinol (Lausanne) 6:74","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1028_CR13","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1038\/onc.2015.229","volume":"35","author":"E Flashner-Abramson","year":"2016","unstructured":"Flashner-Abramson E, Klein S, Mullin G, Shoshan E, Song R, Shir A, Langut Y, Bar-Eli M, Reuveni H, Levitzki A (2016) Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. Oncogene 35:2675\u20132680","journal-title":"Oncogene"},{"key":"1028_CR14","doi-asserted-by":"publisher","first-page":"2634","DOI":"10.1038\/onc.2015.326","volume":"35","author":"E Sanchez-Lopez","year":"2016","unstructured":"Sanchez-Lopez E, Flashner-Abramson E, Shalapour S, Zhong Z, Taniguchi K, Levitzki A, Karin M (2016) Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling. Oncogene 35:2634\u20132644","journal-title":"Oncogene"},{"issue":"6","key":"1028_CR15","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s12672-018-0343-8","volume":"9","author":"Y Yang","year":"2018","unstructured":"Yang Y, Chan JY, Temiz NA, Yee D (2018) Insulin receptor substrate suppression by the tyrphostin NT157 inhibits responses to insulin-like growth factor-I and insulin in breast cancer cells. Horm Cancer 9(6):371\u2013382","journal-title":"Horm Cancer"},{"key":"1028_CR16","first-page":"30","volume-title":"WHO classification of tumors of haematopoietic and lymphoid tissues","author":"JW Vardiman","year":"2017","unstructured":"Vardiman JW, Melo JV, Baccarani M, Radich JP, Kvasnicka HM (2017) Chronic myeloid leukaemi, BCR-ABL1-positive. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (eds) WHO classification of tumors of haematopoietic and lymphoid tissues. IARC, Lyon, pp 30\u201336"},{"key":"1028_CR17","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"TC Chou","year":"2006","unstructured":"Chou TC (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 58:621\u2013681","journal-title":"Pharmacol Rev"},{"key":"1028_CR18","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.4155\/fmc.09.89","volume":"1","author":"MJ Mulvihill","year":"2009","unstructured":"Mulvihill MJ, Cooke A, Rosenfeld-Franklin M, Buck E, Foreman K, Landfair D, O\u2019Connor M, Pirritt C, Sun Y, Yao Y, Arnold LD, Gibson NW, Ji QS (2009) Discovery of OSI-906: a selective and orally efficacious dual inhibitor of the IGF-1 receptor and insulin receptor. Future Med Chem 1:1153\u20131171","journal-title":"Future Med Chem"},{"key":"1028_CR19","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1200\/JCO.2006.09.3534","volume":"25","author":"D Juric","year":"2007","unstructured":"Juric D, Lacayo NJ, Ramsey MC, Racevskis J, Wiernik PH, Rowe JM, Goldstone AH, O\u2019Dwyer PJ, Paietta E, Sikic BI (2007) Differential gene expression patterns and interaction networks in BCR-ABL-positive and -negative adult acute lymphoblastic leukemias. J Clin Oncol 25:1341\u20131349","journal-title":"J Clin Oncol"},{"key":"1028_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41392-019-0102-5","volume":"5","author":"BA Fenerich","year":"2020","unstructured":"Fenerich BA, Fernandes JC, Rodrigues Alves APN, Coelho-Silva JL, Scopim-Ribeiro R, Scheucher PS, Eide CA, Tognon CE, Druker BJ, Rego EM, Machado-Neto JA, Traina F (2020) NT157 has antineoplastic effects and inhibits IRS1\/2 and STAT3\/5 in JAK2V617F-positive myeloproliferative neoplasm cells. Signal Transduction Target Ther 5:5","journal-title":"Signal Transduction Target Ther"},{"key":"1028_CR21","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.1038\/onc.2008.8","volume":"27","author":"A Lakshmikuttyamma","year":"2008","unstructured":"Lakshmikuttyamma A, Pastural E, Takahashi N, Sawada K, Sheridan DP, DeCoteau JF, Geyer CR (2008) Bcr-Abl induces autocrine IGF-1 signaling. Oncogene 27:3831\u20133844","journal-title":"Oncogene"},{"key":"1028_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13045-015-0106-8","volume":"8","author":"J Xie","year":"2015","unstructured":"Xie J, Chen X, Zheng J, Li C, Stacy S, Holzenberger M, Hu X, Zhang CC (2015) IGF-IR determines the fates of BCR\/ABL leukemia. J Hematol Oncol 8:3","journal-title":"J Hematol Oncol"},{"key":"1028_CR23","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nature18288","volume":"534","author":"SA Abraham","year":"2016","unstructured":"Abraham SA, Hopcroft LE, Carrick E, Drotar ME, Dunn K, Williamson AJ, Korfi K, Baquero P, Park LE, Scott MT, Pellicano F, Pierce A, Copland M, Nourse C, Grimmond SM, Vetrie D, Whetton AD, Holyoake TL (2016) Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature 534:341\u2013346","journal-title":"Nature"},{"key":"1028_CR24","doi-asserted-by":"publisher","first-page":"355ra117","DOI":"10.1126\/scitranslmed.aag1180","volume":"8","author":"BZ Carter","year":"2016","unstructured":"Carter BZ, Mak PY, Mu H, Zhou H, Mak DH, Schober W, Leverson JD, Zhang B, Bhatia R, Huang X, Cortes J, Kantarjian H, Konopleva M, Andreeff M (2016) Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Sci Transl Med 8:355ra117","journal-title":"Sci Transl Med"},{"key":"1028_CR25","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.cell.2004.10.010","volume":"119","author":"E Passegue","year":"2004","unstructured":"Passegue E, Wagner EF, Weissman IL (2004) JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells. Cell 119:431\u2013443","journal-title":"Cell"},{"key":"1028_CR26","doi-asserted-by":"publisher","first-page":"3205","DOI":"10.1182\/blood-2002-05-1598","volume":"101","author":"MY Yang","year":"2003","unstructured":"Yang MY, Liu TC, Chang JG, Lin PM, Lin SF (2003) JunB gene expression is inactivated by methylation in chronic myeloid leukemia. Blood 101:3205\u20133211","journal-title":"Blood"},{"key":"1028_CR27","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.leukres.2009.03.044","volume":"33","author":"K Hoshino","year":"2009","unstructured":"Hoshino K, Quintas-Cardama A, Radich J, Dai H, Yang H, Garcia-Manero G (2009) Downregulation of JUNB mRNA expression in advanced phase chronic myelogenous leukemia. Leuk Res 33:1361\u20131366","journal-title":"Leuk Res"},{"key":"1028_CR28","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","volume":"16","author":"T O\u2019Hare","year":"2009","unstructured":"O\u2019Hare T, Shakespeare WC, Zhu X, Eide CA, Rivera VM, Wang F, Adrian LT, Zhou T, Huang WS, Xu Q, Metcalf CA III, Tyner JW, Loriaux MM, Corbin AS, Wardwell S, Ning Y, Keats JA, Wang Y, Sundaramoorthi R, Thomas M, Zhou D, Snodgrass J, Commodore L, Sawyer TK, Dalgarno DC, Deininger MW, Druker BJ, Clackson T (2009) AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 16:401\u2013412","journal-title":"Cancer Cell"},{"key":"1028_CR29","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","volume":"367","author":"JE Cortes","year":"2012","unstructured":"Cortes JE, Kantarjian H, Shah NP, Bixby D, Mauro MJ, Flinn I, O\u2019Hare T, Hu S, Narasimhan NI, Rivera VM, Clackson T, Turner CD, Haluska FG, Druker BJ, Deininger MW, Talpaz M (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075\u20132088","journal-title":"N Engl J Med"},{"key":"1028_CR30","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Muller MC, Gambacorti-Passerini C, Wong S, Lustgarten S, Rivera VM, Clackson T, Turner CD, Haluska FG, Guilhot F, Deininger MW, Hochhaus A, Hughes T, Goldman JM, Shah NP, Kantarjian H (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783\u20131796","journal-title":"N Engl J Med"},{"key":"1028_CR31","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1200\/JCO.2015.62.4718","volume":"33","author":"JJ Moslehi","year":"2015","unstructured":"Moslehi JJ, Deininger M (2015) Tyrosine kinase inhibitor-associated cardiovascular toxicity in chronic myeloid leukemia. J Clin Oncol 33:4210\u20134218","journal-title":"J Clin Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-01028-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-01028-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T05:03:16Z","timestamp":1678510996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-01028-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["1028"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-01028-8","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,6]]},"assertion":[{"value":"24 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Brian J. Druker potential competing interests- SAB: Aileron Therapeutics, ALLCRON, Cepheid, Gilead Sciences, Vivid Biosciences, Celgene & Baxalta (inactive); SAB & Stock: Aptose Biosciences, Blueprint Medicines, Beta Cat, GRAIL, Third Coast Therapeutics, CTI BioPharma (inactive); Scientific Founder & Stock: MolecularMD; Board of Directors & Stock: Amgen; Board of Directors: Burroughs Wellcome Fund, CureOne; Joint Steering Committee: Beat AML LLS; Clinical Trial Funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license). Renata Scopim-Ribeiro declares that she has no conflict of interest. Jo\u00e3o Agostinho Machado-Neto declares that he has no conflict of interest. Christopher A. Eide declares that he has no conflict of interest. Juan Luiz Coelho-Silva declares that he has no conflict of interest. Bruna Alves Fenerich declares that she has no conflict of interest. Jaqueline Cristina Fernandes declares that she has no conflict of interest. Priscila Santos Scheucher declares that she has no conflict of interest. Samantha L. Savage Stevens declares that she has no conflict of interest. Paula de Melo Campos declares that she has no conflict of interest. Sara T. Olalla Saad declares that she has no conflict of interest. Leonardo de Carvalho Palma declares that he has no conflict of interest. Lorena Lobo de Figueiredo-Pontes declares that she has no conflict of interest. Belinda Pinto Sim\u00f5es declares that she has no conflict of interest. Eduardo Magalh\u00e3es Rego declares that he has no conflict of interest. Cristina E. Tognon declares that she has no conflict of interest. Fabiola Traina declares that she has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and with the 1964 Helsinki declaration and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}